Innovative Liquid Biopsy Inivata's pioneering InVision® platform and RaDaR assay enable real-time, minimally invasive genomic profiling for cancer patients, presenting opportunities for healthcare providers and labs seeking advanced diagnostic tools to improve treatment monitoring and personalized care.

Growing Market Presence With its commercial launch of InVisionFirst™-Lung and ongoing clinical studies, Inivata demonstrates a commitment to expanding its footprint in the liquid biopsy market, signaling potential for partnerships and sales of their assays to oncology clinics and research institutions.

Strategic Collaborations Inivata's partnerships with pharmaceutical and biotech companies, along with collaborations with NeoGenomics, position it as a key player in cancer diagnostics, opening avenues for collaborative product development and sales opportunities in clinical trial support and diagnostic services.

Recent Leadership Expansion The appointment of Vishal Sikri as president and chief commercial officer highlights a focus on expanding commercialization efforts, indicating sales growth potential and increased market outreach to oncology research centers and healthcare providers.

Funding and Growth With $35 million in funding and a revenue range of $1 million to $10 million, Inivata is positioned for scale-up, providing opportunities for sales teams to target mid-sized research labs, hospitals, and diagnostic companies seeking innovative liquid biopsy solutions.